AR016681A1 - DEPECTION OF TH2 CELLS; COMPOSITIONS; METHODS - Google Patents

DEPECTION OF TH2 CELLS; COMPOSITIONS; METHODS

Info

Publication number
AR016681A1
AR016681A1 ARP980105731A ARP980105731A AR016681A1 AR 016681 A1 AR016681 A1 AR 016681A1 AR P980105731 A ARP980105731 A AR P980105731A AR P980105731 A ARP980105731 A AR P980105731A AR 016681 A1 AR016681 A1 AR 016681A1
Authority
AR
Argentina
Prior art keywords
cells
compositions
depection
methods
ccr8
Prior art date
Application number
ARP980105731A
Other languages
Spanish (es)
Original Assignee
Schering Corp
Napolitano Monica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Napolitano Monica filed Critical Schering Corp
Publication of AR016681A1 publication Critical patent/AR016681A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan composiciones de union que se unen selectivamente a un marcador específicamente encontrado en las células Th2 y varios métodos de uso delas composiciones de union. En particular, el método hace uso del hecho que el receptor CCR8 dequ emoquina se expresa selectivamente en el subconjunto decélulas Th2. Preferentemente, la composicion de union es un anticuerpo monoclonal específico para CCR8.Binding compositions are provided that selectively bind to a marker specifically found in Th2 cells and various methods of using binding compositions. In particular, the method makes use of the fact that the CCR8 dequ emoquine receptor is selectively expressed in the Th2 cell subset. Preferably, the binding composition is a monoclonal antibody specific for CCR8.

ARP980105731A 1997-11-13 1998-11-12 DEPECTION OF TH2 CELLS; COMPOSITIONS; METHODS AR016681A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6539297P 1997-11-13 1997-11-13

Publications (1)

Publication Number Publication Date
AR016681A1 true AR016681A1 (en) 2001-07-25

Family

ID=22062409

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105731A AR016681A1 (en) 1997-11-13 1998-11-12 DEPECTION OF TH2 CELLS; COMPOSITIONS; METHODS

Country Status (7)

Country Link
EP (1) EP1030865A2 (en)
JP (1) JP2001523446A (en)
AR (1) AR016681A1 (en)
AU (1) AU1373099A (en)
CA (1) CA2309761A1 (en)
WO (1) WO1999025734A2 (en)
ZA (1) ZA9810371B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416954B1 (en) * 1999-02-08 2002-07-09 Schering Corporation Modulating Th2 cell levels via vMIP-I/CCR8 interaction
WO2001058484A2 (en) * 2000-02-10 2001-08-16 Schering Corporation Novel uses of mammalian ccr8 receptors and related reagents
US6762341B2 (en) 2000-02-10 2004-07-13 Schering Corporation Uses of mammalian CCR8 receptors and related reagents
WO2003096020A2 (en) * 2002-05-13 2003-11-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2007044756A2 (en) * 2005-10-11 2007-04-19 Icos Corporation Monoclonal antibodies recognizing human ccr8
WO2014082993A2 (en) * 2012-11-30 2014-06-05 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the down-regulation of the th2 response
WO2017198631A1 (en) * 2016-05-16 2017-11-23 Istituto Nazionale Di Genetica Molecolare - Ingm Markers selectively deregulated in tumor-infiltrating regulatory t cells
SG11202106214YA (en) * 2018-12-27 2021-07-29 Shionogi & Co Novel anti-ccr8 antibody
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
WO2023219147A1 (en) * 2022-05-13 2023-11-16 塩野義製薬株式会社 Novel anti-ccr8 antibodies for detecting ccr8

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
EP0843557B1 (en) * 1995-07-21 2002-11-13 Applied Research Systems ARS Holding N.V. Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein
JP3144805B2 (en) * 1996-06-05 2001-03-12 株式会社 ビー・エム・エル Human Th2-specific protein and gene encoding the same (B19) and transformants, recombinant vectors and monoclonal antibodies related thereto

Also Published As

Publication number Publication date
ZA9810371B (en) 1999-08-30
CA2309761A1 (en) 1999-05-27
WO1999025734A2 (en) 1999-05-27
WO1999025734A3 (en) 1999-07-15
JP2001523446A (en) 2001-11-27
AU1373099A (en) 1999-06-07
EP1030865A2 (en) 2000-08-30

Similar Documents

Publication Publication Date Title
CL2010001209A1 (en) Isolated monoclonal antibodies that preferentially bind to the ca 125 / o772p polypeptide associated with cells in relation to the soluble ca 125 / o772p polypeptide; hybridoma; nucleic acid that encodes them; pharmaceutical composition; fusion polypeptide kit; and its use to prepare a medicament for treating a proliferative cell disorder (divisional sol. No. 2086-03).
BRPI0510716A (en) use of a bispecific binding agent, bispecific binding agent, composition of a bispecific binding agent, and kit
ECSP034490A (en) ANTIBODIES FOR THE HUMAN IL-1B
AR016681A1 (en) DEPECTION OF TH2 CELLS; COMPOSITIONS; METHODS
BR112022013756A2 (en) ANTI-TRAIN2 ANTIBODIES AND METHODS OF USE THEREOF
ATE296348T1 (en) CYTOKINE LERK-7
ES2118820T3 (en) MONOCLONAL ANTIBODIES FOR RECEPTORS OF PLURIPOTENT CELL FACTORS.
DE69406423D1 (en) METHOD FOR DELIVERING AGENTS TO TARGET CELLS
AR064801A1 (en) PRLR SPECIFIC ANTIBODY (PROLACTIN RECEPTOR) AND ITS USES
BRPI0820885B8 (en) "antibody or fragment thereof, hybridoma cell, polynucleotide, polypeptide comprising an antibody heavy or light chain domain, method for detecting pregnancy in a bovine animal, kit and method for purifying a major antigen associated with pregnancy (pag)" .
BRPI0814343A2 (en) MATERIALS AND METHODS FOR SPERM SEXING SELECTION
ATE267596T1 (en) CYANIDINE COMPOSITIONS AND THEIR THERAPEUTIC AND DIAGNOSTIC USES
ES2110993T3 (en) MONOCLONAL ANTIBODIES SPECIFIC TO CLOSTRIDIUM DIFFICILE TOXIN B.
ES2194024T3 (en) A PROTEIN OF CELL SURFACE, DENOMINATED PROTEIN RIB, WHICH CONFERTS IMMUNITY TO MANY STREPTOCOCO BODIES OF GROUP B; PROCEDURE TO PURIFY THE PROTEIN, KIT OF REAGENTS AND PHARMACEUTICAL COMPOSITION.
BR0116686A (en) Silenced anti-cd28 Antibodies and usage
ATE132162T1 (en) HUMAN GAMMA INTERFERON ANTAGONISTS
ATE202117T1 (en) ANGIOTENSIN II RECEPTOR TYPE I SPECIFIC MONOCLONAL ANTIBODIES AND HYBRIDOMA
PT1047449E (en) IMMUNOLOGICAL COMPOSITIONS AND METHODS OF USE FOR TRANSITORIAMENTALLY CHANGING MYELIN OF THE CENTRAL NERVOSO MAMIFERO SYSTEM TO PROMOTE NEURONAL REGENERATION
DE69434828D1 (en) Monoclonal antibodies recognize the Flk-2 receptors, and the isolation of primitive hematopoietic stem cell populations
AR023904A1 (en) ANTIBODIES FOR THE ANTIGEN OF DENDRITIC CELLS AND THEIR USES
FR2756827B1 (en) SYNTHETIC BIEPITOPIC COMPOUNDS FOR USE AS STANDARDS IN BIOLOGICAL ASSAYS FOR TROPONIN I
ES2112211B1 (en) PROCEDURE FOR THE STUDY OF THE CELL CYCLE OF SUB-POPULATIONS OF CELLS PRESENT IN HETEROGENEOUS CELL SAMPLES.
ES2159763T3 (en) (ETER) FATTY ALCOHOL SULPHATES WITH COLD IMPROVED BEHAVIOR.
AR037216A1 (en) HCV ANTINUCLEAR MONOCLONAL ANTIBODIES
ES1010307U (en) Municipal post. (Machine-translation by Google Translate, not legally binding)

Legal Events

Date Code Title Description
FB Suspension of granting procedure